Skip to main content
Erschienen in: Cellular Oncology 2/2014

01.04.2014 | Original Paper

Transcription of the vascular endothelial growth factor receptor-3 (VEGFR3) gene is regulated by the zinc finger proteins Sp1 and Sp3 and is under epigenetic control

Transcription of vascular endothelial growth factor receptor 3

verfasst von: Johannes Hertel, Christoph Hirche, Christoph Wissmann, Matthias P. Ebert, Michael Höcker

Erschienen in: Cellular Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

In the past, the vascular endothelial growth factor receptor-3 (VEGFR-3) has been linked to the regulation of lymphangiogenesis and the lymphatic spread of solid malignancies. The molecular mechanisms controlling VEGFR3 gene expression have, however, remained poorly understood. Here, we aimed at assessing these mechanisms through VEGFR3 gene promoter analysis and the identification of transcription factors binding to it. In addition, we focussed on epigenetic modifications underlying VEGFR3 transcription regulation.

Methods

5′ Deletion analyses for the identification of functional promoter elements, electrophoretic mobility shift assays, chromatin immunoprecipitations, methylation-specific PCRs, and Trichostatin A (TSA) and 5-Aza desoxycytidine (5-Aza dC) treatments were performed in this study.

Results

Following the isolation of a 2 kb stretch of 5′-flanking DNA of VEGFR3, we identified a novel GC-rich element (GRE) spanning −101/−66 sufficient for VEGFR3 transcription and activated by Sp1 and Sp3, respectively. Histone de-acetylase inhibition by TSA led to the accumulation of acetylated histones H3/H4 at the VEGFR3 gene promoter, up-regulation of its mRNA levels, and transactivation of promoter reporter constructs in endothelial cell lines. Similarly, methylation inhibition by 5-Aza dC triggered up-regulation of VEGFR3 mRNA levels and increased promoter activity. TSA and 5-Aza-dC did not influence Sp1/Sp3 binding, but increased the transactivating capacity of both transcription factors, suggesting epigenetic modification as an underlying mechanism.

Conclusions

Here we describe the identification of regulatory elements controlling human VEGFR3 gene expression and show that histone acetylation and CpG methylation are important determinants of VEGFR3 transcription regulation. These findings may facilitate the development of intervention strategies aimed at targeting VEGFR3-based tumor lymphangiogenesis and/or lymphatic tumor spread.
Literatur
1.
Zurück zum Zitat G.D. Yancopoulos, S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand, J. Holash, Vascular-specific growth factors and blood vessel formation. Nature 407(6801), 242–248 (2000)PubMedCrossRef G.D. Yancopoulos, S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand, J. Holash, Vascular-specific growth factors and blood vessel formation. Nature 407(6801), 242–248 (2000)PubMedCrossRef
2.
Zurück zum Zitat G. Neufeld, T. Cohen, S. Gengrinovitch, Z. Poltorak, Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13(1), 9–22 (1999)PubMed G. Neufeld, T. Cohen, S. Gengrinovitch, Z. Poltorak, Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13(1), 9–22 (1999)PubMed
3.
Zurück zum Zitat Y. Yokoyama, D.S. Charnock-Jones, D. Licence, A. Yanaihara, J.M. Hastings, C.M. Holland, M. Emoto, A. Sakamoto, T. Sakamoto, H. Maruyama, S. Sato, H. Mizunuma, S.K. Smith, Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin. Cancer Res. 9(4), 1361–1369 (2003)PubMed Y. Yokoyama, D.S. Charnock-Jones, D. Licence, A. Yanaihara, J.M. Hastings, C.M. Holland, M. Emoto, A. Sakamoto, T. Sakamoto, H. Maruyama, S. Sato, H. Mizunuma, S.K. Smith, Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin. Cancer Res. 9(4), 1361–1369 (2003)PubMed
4.
Zurück zum Zitat M. Arinaga, T. Noguchi, S. Takeno, M. Chujo, T. Miura, Y. Uchida, Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97(2), 457–464 (2003)PubMedCrossRef M. Arinaga, T. Noguchi, S. Takeno, M. Chujo, T. Miura, Y. Uchida, Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97(2), 457–464 (2003)PubMedCrossRef
5.
Zurück zum Zitat Y. Nakamura, H. Yasuoka, M. Tsujimoto, Q. Yang, S. Imabun, M. Nakahara, K. Nakao, M. Nakamura, I. Mori, K. Kakudo, Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin. Cancer Res. 9(14), 5313–5317 (2003)PubMed Y. Nakamura, H. Yasuoka, M. Tsujimoto, Q. Yang, S. Imabun, M. Nakahara, K. Nakao, M. Nakamura, I. Mori, K. Kakudo, Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin. Cancer Res. 9(14), 5313–5317 (2003)PubMed
6.
Zurück zum Zitat Y. Yonemura, S. Fushida, E. Bando, K. Kinoshita, K. Miwa, Y. Endo, K. Sugiyama, T. Partanen, H. Yamamoto, T. Sasaki, Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur. J. Cancer 37(7), 918–923 (2001)PubMedCrossRef Y. Yonemura, S. Fushida, E. Bando, K. Kinoshita, K. Miwa, Y. Endo, K. Sugiyama, T. Partanen, H. Yamamoto, T. Sasaki, Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur. J. Cancer 37(7), 918–923 (2001)PubMedCrossRef
7.
Zurück zum Zitat Y. Yokoyama, D.S. Charnock-Jones, D. Licence, A. Yanaihara, J.M. Hastings, C.M. Holland, M. Emoto, M. Umemoto, T. Sakamoto, S. Sato, H. Mizunuma, S.K. Smith, Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br. J. Cancer 88(2), 237–244 (2003)PubMedCentralPubMedCrossRef Y. Yokoyama, D.S. Charnock-Jones, D. Licence, A. Yanaihara, J.M. Hastings, C.M. Holland, M. Emoto, M. Umemoto, T. Sakamoto, S. Sato, H. Mizunuma, S.K. Smith, Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br. J. Cancer 88(2), 237–244 (2003)PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat K. Shimizu, H. Kubo, K. Yamaguchi, K. Kawashima, Y. Ueda, K. Matsuo, M. Awane, Y. Shimahara, A. Takabayashi, Y. Yamaoka, S. Satoh, Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci. 95(4), 328–333 (2004)PubMedCrossRef K. Shimizu, H. Kubo, K. Yamaguchi, K. Kawashima, Y. Ueda, K. Matsuo, M. Awane, Y. Shimahara, A. Takabayashi, Y. Yamaoka, S. Satoh, Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci. 95(4), 328–333 (2004)PubMedCrossRef
9.
Zurück zum Zitat H. Yang, M. Li, H. Chai, S. Yan, R. Zhang, Q. Yao, C. Chen, Expression and regulation of neuropilins and VEGF receptors by TNF-alpha in human endothelial cells. J. Surg. Res. 122(2), 249–255 (2004)PubMedCrossRef H. Yang, M. Li, H. Chai, S. Yan, R. Zhang, Q. Yao, C. Chen, Expression and regulation of neuropilins and VEGF receptors by TNF-alpha in human endothelial cells. J. Surg. Res. 122(2), 249–255 (2004)PubMedCrossRef
10.
Zurück zum Zitat F.C. Connell, P. Ostergaard, C. Carver, G. Brice, N. Williams, S. Mansour, P.S. Mortimer, S. Jeffery, Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas. Hum. Genet. 124(6), 625–631 (2009)PubMedCrossRef F.C. Connell, P. Ostergaard, C. Carver, G. Brice, N. Williams, S. Mansour, P.S. Mortimer, S. Jeffery, Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas. Hum. Genet. 124(6), 625–631 (2009)PubMedCrossRef
11.
Zurück zum Zitat C.J. Shawber, Y. Funahashi, E. Francisco, M. Vorontchikhina, Y. Kitamura, S.A. Stowell, V. Borisenko, N. Feirt, S. Podgrabinska, K. Shiraishi, K. Chawengsaksophak, J. Rossant, D. Accili, M. Skobe, J. Kitajewski, Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J. Clin. Invest. 117(11), 3369–3382 (2007)PubMedCentralPubMedCrossRef C.J. Shawber, Y. Funahashi, E. Francisco, M. Vorontchikhina, Y. Kitamura, S.A. Stowell, V. Borisenko, N. Feirt, S. Podgrabinska, K. Shiraishi, K. Chawengsaksophak, J. Rossant, D. Accili, M. Skobe, J. Kitajewski, Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J. Clin. Invest. 117(11), 3369–3382 (2007)PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat K. Iljin, M.J. Karkkainen, E.C. Lawrence, M.A. Kimak, M. Uutela, J. Taipale, K. Pajusola, L. Alhonen, M. Halmekyto, D.N. Finegold, R.E. Ferrell, K. Alitalo, VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15(6), 1028–1036 (2001)PubMedCrossRef K. Iljin, M.J. Karkkainen, E.C. Lawrence, M.A. Kimak, M. Uutela, J. Taipale, K. Pajusola, L. Alhonen, M. Halmekyto, D.N. Finegold, R.E. Ferrell, K. Alitalo, VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15(6), 1028–1036 (2001)PubMedCrossRef
14.
Zurück zum Zitat M. Abdelrahim, R. Smith III, R. Burghardt, S. Safe, Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. 64(18), 6740–6749 (2004)PubMedCrossRef M. Abdelrahim, R. Smith III, R. Burghardt, S. Safe, Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. 64(18), 6740–6749 (2004)PubMedCrossRef
15.
Zurück zum Zitat M. Abdelrahim, C.H. Baker, J.L. Abbruzzese, D. Sheikh-Hamad, S. Liu, S.D. Cho, K. Yoon, S. Safe, Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res. 67(7), 3286–3294 (2007)PubMedCrossRef M. Abdelrahim, C.H. Baker, J.L. Abbruzzese, D. Sheikh-Hamad, S. Liu, S.D. Cho, K. Yoon, S. Safe, Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res. 67(7), 3286–3294 (2007)PubMedCrossRef
16.
Zurück zum Zitat K.J. Higgins, M. Abdelrahim, S. Liu, K. Yoon, S. Safe, Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem. Biophys. Res. Commun. 345(1), 292–301 (2006)PubMedCrossRef K.J. Higgins, M. Abdelrahim, S. Liu, K. Yoon, S. Safe, Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem. Biophys. Res. Commun. 345(1), 292–301 (2006)PubMedCrossRef
17.
Zurück zum Zitat G. Schäfer, T. Cramer, G. Suske, W. Kemmner, B. Wiedenmann, M. Höcker, Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J. Biol. Chem. 278(10), 8190–8198 (2003)PubMedCrossRef G. Schäfer, T. Cramer, G. Suske, W. Kemmner, B. Wiedenmann, M. Höcker, Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J. Biol. Chem. 278(10), 8190–8198 (2003)PubMedCrossRef
18.
Zurück zum Zitat Strowski MZ, Cramer T, Schafer G, Juttner S, Walduck A, Schipani E, Kemmner W, Wessler S, Wunder C, Weber M, Meyer TF, Wiedenmann B, Jons T, Naumann M, Hocker M: Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. FASEB J. 18(1), 218–220 (2004) Strowski MZ, Cramer T, Schafer G, Juttner S, Walduck A, Schipani E, Kemmner W, Wessler S, Wunder C, Weber M, Meyer TF, Wiedenmann B, Jons T, Naumann M, Hocker M: Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. FASEB J. 18(1), 218–220 (2004)
19.
Zurück zum Zitat S. Juttner, C. Wissmann, T. Jons, M. Vieth, J. Hertel, S. Gretschel, P.M. Schlag, W. Kemmner, M. Hocker, Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J. Clin. Oncol. 24(2), 228–240 (2006)PubMedCrossRef S. Juttner, C. Wissmann, T. Jons, M. Vieth, J. Hertel, S. Gretschel, P.M. Schlag, W. Kemmner, M. Hocker, Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J. Clin. Oncol. 24(2), 228–240 (2006)PubMedCrossRef
20.
Zurück zum Zitat P. Chomczynski, A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15(3), 532–537 (1993)PubMed P. Chomczynski, A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15(3), 532–537 (1993)PubMed
21.
Zurück zum Zitat X.P. Dong, H. Pfister, Overlapping YY1- and aberrant SP1-binding sites proximal to the early promoter of human papillomavirus type 16. J. Gen. Virol. 80(8), 2097–2101 (1999)PubMed X.P. Dong, H. Pfister, Overlapping YY1- and aberrant SP1-binding sites proximal to the early promoter of human papillomavirus type 16. J. Gen. Virol. 80(8), 2097–2101 (1999)PubMed
22.
Zurück zum Zitat G. Finkenzeller, A. Sparacio, A. Technau, D. Marme, G. Siemeister, Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15(6), 669–676 (1997)PubMedCrossRef G. Finkenzeller, A. Sparacio, A. Technau, D. Marme, G. Siemeister, Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15(6), 669–676 (1997)PubMedCrossRef
23.
Zurück zum Zitat C. Ji, S. Casinghino, T.L. McCarthy, M. Centrella, Multiple and essential Sp1 binding sites in the promoter for transforming growth factor-beta type I receptor. J. Biol. Chem. 272(34), 21260–21267 (1997)PubMedCrossRef C. Ji, S. Casinghino, T.L. McCarthy, M. Centrella, Multiple and essential Sp1 binding sites in the promoter for transforming growth factor-beta type I receptor. J. Biol. Chem. 272(34), 21260–21267 (1997)PubMedCrossRef
24.
Zurück zum Zitat M. Ryuto, M. Ono, H. Izumi, S. Yoshida, H.A. Weich, K. Kohno, M. Kuwano, Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J. Biol. Chem. 271(45), 28220–28228 (1996)PubMedCrossRef M. Ryuto, M. Ono, H. Izumi, S. Yoshida, H.A. Weich, K. Kohno, M. Kuwano, Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J. Biol. Chem. 271(45), 28220–28228 (1996)PubMedCrossRef
25.
Zurück zum Zitat S.P. Jackson, J.J. MacDonald, S. Lees-Miller, R. Tjian, GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell 63(1), 155–165 (1990)PubMedCrossRef S.P. Jackson, J.J. MacDonald, S. Lees-Miller, R. Tjian, GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell 63(1), 155–165 (1990)PubMedCrossRef
26.
Zurück zum Zitat S. Chupreta, M. Du, A. Todisco, J.L. Merchant, EGF stimulates gastrin promoter through activation of Sp1 kinase activity. Am. J. Physiol. Cell Physiol. 278(4), C697–C708 (2000)PubMed S. Chupreta, M. Du, A. Todisco, J.L. Merchant, EGF stimulates gastrin promoter through activation of Sp1 kinase activity. Am. J. Physiol. Cell Physiol. 278(4), C697–C708 (2000)PubMed
27.
Zurück zum Zitat I. Alroy, L. Soussan, R. Seger, Y. Yarden, Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor. Mol. Cell. Biol. 19(3), 1961–1972 (1999)PubMedCentralPubMed I. Alroy, L. Soussan, R. Seger, Y. Yarden, Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor. Mol. Cell. Biol. 19(3), 1961–1972 (1999)PubMedCentralPubMed
28.
Zurück zum Zitat J.L. Merchant, M. Du, A. Todisco, Sp1 phosphorylation by Erk 2 stimulates DNA binding. Biochem. Biophys. Res. Commun. 254(2), 454–461 (1999)PubMedCrossRef J.L. Merchant, M. Du, A. Todisco, Sp1 phosphorylation by Erk 2 stimulates DNA binding. Biochem. Biophys. Res. Commun. 254(2), 454–461 (1999)PubMedCrossRef
29.
Zurück zum Zitat H.S. Choi, J.H. Lee, J.G. Park, Y.I. Lee, Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex. Biochem. Biophys. Res. Commun. 296(4), 1005–1012 (2002)PubMedCrossRef H.S. Choi, J.H. Lee, J.G. Park, Y.I. Lee, Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex. Biochem. Biophys. Res. Commun. 296(4), 1005–1012 (2002)PubMedCrossRef
30.
Zurück zum Zitat M. Meissner, G. Reichenbach, M. Stein, I. Hrgovic, R. Kaufmann, J. Gille, Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells. Cancer Res. 69(5), 1976–1984 (2009)PubMedCrossRef M. Meissner, G. Reichenbach, M. Stein, I. Hrgovic, R. Kaufmann, J. Gille, Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells. Cancer Res. 69(5), 1976–1984 (2009)PubMedCrossRef
31.
Zurück zum Zitat Q. Shi, X. Le, J.L. Abbruzzese, Z. Peng, C.N. Qian, H. Tang, Q. Xiong, B. Wang, X.C. Li, K. Xie, Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 61(10), 4143–4154 (2001)PubMed Q. Shi, X. Le, J.L. Abbruzzese, Z. Peng, C.N. Qian, H. Tang, Q. Xiong, B. Wang, X.C. Li, K. Xie, Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 61(10), 4143–4154 (2001)PubMed
32.
Zurück zum Zitat J.C. Yao, L. Wang, D. Wei, W. Gong, M. Hassan, T.T. Wu, P. Mansfield, J. Ajani, K. Xie, Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin. Cancer Res. 10(12 Pt 1), 4109–4117 (2004)PubMedCrossRef J.C. Yao, L. Wang, D. Wei, W. Gong, M. Hassan, T.T. Wu, P. Mansfield, J. Ajani, K. Xie, Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin. Cancer Res. 10(12 Pt 1), 4109–4117 (2004)PubMedCrossRef
33.
Zurück zum Zitat L. Wang, D. Wei, S. Huang, Z. Peng, X. Le, T.T. Wu, J. Yao, J. Ajani, K. Xie, Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin. Cancer Res. 9(17), 6371–6380 (2003)PubMed L. Wang, D. Wei, S. Huang, Z. Peng, X. Le, T.T. Wu, J. Yao, J. Ajani, K. Xie, Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin. Cancer Res. 9(17), 6371–6380 (2003)PubMed
34.
Zurück zum Zitat P.A. Jones, S.B. Baylin, The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415–428 (2002)PubMed P.A. Jones, S.B. Baylin, The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415–428 (2002)PubMed
35.
Zurück zum Zitat P.A. Marks, V.M. Richon, R. Breslow, R.A. Rifkind, Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13(6), 477–483 (2001)PubMedCrossRef P.A. Marks, V.M. Richon, R. Breslow, R.A. Rifkind, Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13(6), 477–483 (2001)PubMedCrossRef
36.
Zurück zum Zitat L.Y. Mie, S.H. Kim, H.S. Kim, S.M. Jin, H. Nakajima, K.H. Jeong, K.W. Kim, Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun. 300(1), 241–246 (2003)CrossRef L.Y. Mie, S.H. Kim, H.S. Kim, S.M. Jin, H. Nakajima, K.H. Jeong, K.W. Kim, Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun. 300(1), 241–246 (2003)CrossRef
37.
Zurück zum Zitat M.S. Kim, H.J. Kwon, Y.M. Lee, J.H. Baek, J.E. Jang, S.W. Lee, E.J. Moon, H.S. Kim, S.K. Lee, H.Y. Chung, C.W. Kim, K.W. Kim, Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7(4), 437–443 (2001)PubMedCrossRef M.S. Kim, H.J. Kwon, Y.M. Lee, J.H. Baek, J.E. Jang, S.W. Lee, E.J. Moon, H.S. Kim, S.K. Lee, H.Y. Chung, C.W. Kim, K.W. Kim, Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7(4), 437–443 (2001)PubMedCrossRef
38.
Zurück zum Zitat G. Hagen, J. Dennig, A. Preiss, M. Beato, G. Suske, Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3. J. Biol. Chem. 270(42), 24989–24994 (1995)PubMedCrossRef G. Hagen, J. Dennig, A. Preiss, M. Beato, G. Suske, Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3. J. Biol. Chem. 270(42), 24989–24994 (1995)PubMedCrossRef
39.
Zurück zum Zitat P.A. Marks, T. Miller, V.M. Richon, Histone deacetylases. Curr. Opin. Pharmacol. 3(4), 344–351 (2003)PubMedCrossRef P.A. Marks, T. Miller, V.M. Richon, Histone deacetylases. Curr. Opin. Pharmacol. 3(4), 344–351 (2003)PubMedCrossRef
40.
Zurück zum Zitat T.E. Swingler, L. Kevorkian, K.L. Culley, S.A. Illman, D.A. Young, A.E. Parker, J. Lohi, I.M. Clark, MMP28 gene expression is regulated by Sp1 transcription factor acetylation. Biochem. J. 427(3), 391–400 (2010)PubMedCrossRef T.E. Swingler, L. Kevorkian, K.L. Culley, S.A. Illman, D.A. Young, A.E. Parker, J. Lohi, I.M. Clark, MMP28 gene expression is regulated by Sp1 transcription factor acetylation. Biochem. J. 427(3), 391–400 (2010)PubMedCrossRef
41.
Zurück zum Zitat J. Gao, T. Chen, J. Liu, W. Liu, G. Hu, X. Guo, B. Yin, Y. Gong, J. Zhao, B. Qiang, J. Yuan, X. Peng, Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site. Glia 57(9), 989–999 (2009)PubMedCrossRef J. Gao, T. Chen, J. Liu, W. Liu, G. Hu, X. Guo, B. Yin, Y. Gong, J. Zhao, B. Qiang, J. Yuan, X. Peng, Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site. Glia 57(9), 989–999 (2009)PubMedCrossRef
42.
Zurück zum Zitat L.T. Lee, K.C. Tan-Un, R.T. Pang, D.T. Lam, B.K. Chow, Regulation of the human secretin gene is controlled by the combined effects of CpG methylation, Sp1/Sp3 ratio, and the E-box element. Mol. Endocrinol. 18(7), 1740–1755 (2004)PubMedCrossRef L.T. Lee, K.C. Tan-Un, R.T. Pang, D.T. Lam, B.K. Chow, Regulation of the human secretin gene is controlled by the combined effects of CpG methylation, Sp1/Sp3 ratio, and the E-box element. Mol. Endocrinol. 18(7), 1740–1755 (2004)PubMedCrossRef
43.
Zurück zum Zitat R.T. Pang, L.T. Lee, S.S. Ng, W.H. Yung, B.K. Chow, CpG methylation and transcription factors Sp1 and Sp3 regulate the expression of the human secretin receptor gene. Mol. Endocrinol. 18(2), 471–483 (2004)PubMedCrossRef R.T. Pang, L.T. Lee, S.S. Ng, W.H. Yung, B.K. Chow, CpG methylation and transcription factors Sp1 and Sp3 regulate the expression of the human secretin receptor gene. Mol. Endocrinol. 18(2), 471–483 (2004)PubMedCrossRef
Metadaten
Titel
Transcription of the vascular endothelial growth factor receptor-3 (VEGFR3) gene is regulated by the zinc finger proteins Sp1 and Sp3 and is under epigenetic control
Transcription of vascular endothelial growth factor receptor 3
verfasst von
Johannes Hertel
Christoph Hirche
Christoph Wissmann
Matthias P. Ebert
Michael Höcker
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 2/2014
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-014-0169-5

Weitere Artikel der Ausgabe 2/2014

Cellular Oncology 2/2014 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …